About Qi Cao
- A family of proteins known as the Polycomb Group (PcG) regulates gene expression in cellular development in normal cells, and is partially responsible for gene expression dysregulation in cancer.
- PcG proteins are upregulated in prostate cancer and promote disease progression and metastasis. Therefore, these proteins are therapeutic targets.
- One specific PcG protein is named EZH2. Inhibitors of EZH2 will be investigated for the treatment of advanced metastatic prostate cancer.
What this means for patients: Dr. Cao is working on unraveling the underlying mechanisms that lead to cancer progression and the development of treatment resistance. He will also evaluate a combination of two targeted inhibitors of EZH2 for the treatment of advanced prostate cancer.
2013 Michael & Lori Milken-PCF Young Investigator
Qi Cao, PhD
Houston Methodist Research Institute
Arul Chinnaiyan, MD, PhD
A novel role for Polycomb Group proteins in androgen signaling and prostate cancer